High efficiency of the pan-PI3K/mTOR inhibitor, PQR-309, in MCL

被引：0
|
作者：
Kvint, R. [1 ]
Zimmermann, Y. [1 ]
Hutter, G. [1 ]
Hiddemann, W. [1 ]
Dreyling, M. [1 ]
机构：
[1] Klinikum Univ Munchen, Med Klin 3, Munich, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P524
引用
收藏
页码：153 / 154
页数：2
相关论文
共 50 条
  • [21] Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors
    Dehnhardt, Christoph M.
    Venkatesan, Aranapakam M.
    Chen, Zecheng
    Delos-Santos, Efren
    Ayral-Kaloustian, Semiramis
    Brooijmans, Natasja
    Yu, Ker
    Hollander, Irwin
    Feldberg, Larry
    Lucas, Judy
    Mallon, Robert
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (16) : 4773 - 4778
  • [22] A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors
    Janku, Filip
    Choong, Grace M.
    Opyrchal, Mateusz
    Dowlati, Afshin
    Hierro, Cinta
    Rodon, Jordi
    Wicki, Andreas
    Forster, Martin D.
    Blagden, Sarah P.
    Yin, Jun
    Reid, Joel M.
    Muller, Helene
    Cmiljanovic, Natasa
    Cmiljanovic, Vladimir
    Adjei, Alex A.
    CANCERS, 2024, 16 (06)
  • [23] Pre-clinical activity and mechanism of action of the novel dual PI3K/mTOR inhibitor PQR309 in B-cell lymphomas
    Tarantelli, Chiara
    Gaudio, Eugenio
    Kwee, Ivo
    Rinaldi, Andrea
    Bernasconi, Elena
    Cascione, Luciano
    Hillmann, Petra
    Stathis, Anastasios
    Carrassa, Laura
    Broggini, Massimo
    Stussi, Georg
    Fabbro, Doriano
    Beaufils, Florent
    Melone, Anna
    Bohnacker, Thomas
    Wymann, Matthias P.
    Wicki, Andreas
    Zucca, Emanuele
    Cmiljanovic, Vladimir
    Bertoni, Francesco
    CANCER RESEARCH, 2015, 75
  • [24] Novel pan-PIM/pan-PI3K/mTOR inhibitors are highly active in preclinical models of pancreatic ductal adenocarcinoma
    O'Hayer, Kevin
    Barbe, John
    Nevler, Avinoam
    O'Neill, Michael
    Cunningham, Darren
    Winter, Jordan
    Brody, Jonathan
    CANCER RESEARCH, 2016, 76
  • [25] The Dual PI3K/mTOR Inhibitor PQR309 Has Synergistic Activity with Other Targeted Agents in Diffuse Large B Cell Lymphomas
    Tarantelli, Chiara
    Gaudio, Eugenio
    Kwee, Ivo
    Cascione, Luciano
    Bernasconi, Elena
    Hillmann, Petra
    Stathis, Anastasios
    Stussi, Georg
    Fabbro, Doriano
    Wicki, Andreas
    Zucca, Emanuele
    Cmiljanovic, Vladimir
    Bertoni, Francesco
    BLOOD, 2015, 126 (23)
  • [26] Gedatolisib, a well-tolerated pan-PI3K/mTOR inhibitor, exhibits potent therapeutic effects on endometrial cancer models regardless of their PI3K pathway mutational status
    Rossetti, Stefano
    Broege, Aaron
    MacNeil, Ian
    Rich, Ben
    Molden, Jhomary
    Sullivan, Brian
    Laing, Lance
    CANCER RESEARCH, 2023, 83 (07)
  • [27] The dual PI3K/MTOR inhibitor PQR309 is active in mature B cell lymphoma cell lines bearing resistance to the PI3K-delta inhibitor idelalisib and specific gene expression features
    Chiara, Tarantelli
    Gaudio, Eugenio
    Kwee, Ivo
    Arribas, Alberto
    Rinaldi, Andrea
    Bernasconi, Elena
    Cascione, Luciano
    Hillmann, Petra
    Stathis, Anastasios
    Carrassa, Laura
    Broggini, Massimo
    Stussi, Georg
    Fabbro, Doriano
    Zucca, Emanuele
    Cmiljanovic, Vladimir
    Bertoni, Francesco
    CANCER RESEARCH, 2016, 76
  • [28] Ex vivo and in vivo effects of NVP-BEZ235, a dual pan-PI3K / mTOR inhibitor, on insulin signaling and metabolic regulation
    Schnell, Christian
    Brachmann, Saskia
    Arnal, Samuel
    Fritsch, Christine
    Garcia-Echeverria, Carlos
    Sauveur-Maira, Michel
    CANCER RESEARCH, 2009, 69
  • [29] A high affinity pan-PI3K binding module supports selective targeted protein degradation of PI3Kα
    Jauslin, Werner Theodor
    Schild, Matthias
    Schaefer, Thorsten
    Borsari, Chiara
    Orbegozo, Clara
    Bissegger, Lukas
    Zhanybekova, Saule
    Ritz, Danilo
    Schmidt, Alexander
    Wymann, Matthias
    Gillingham, Dennis
    CHEMICAL SCIENCE, 2024, 15 (02) : 683 - 691
  • [30] PI3K pathway (PI3Kp) dysregulation and response to pan-PI3K/AKT/mTOR/dual PI3K-mTOR inhibitors (PI3Kpi) in metastatic breast cancer (MBC) patients (pts).
    Oliveira, Mafalda
    Navarro, Alejandro
    De Mattos-Arruda, Leticia
    Sanchez-Olle, Gessami
    Bellet, Meritxell
    Balmana, Judith
    Gomez-Pardo, Patricia
    Manuel Perez-Garcia, Jose
    Munoz-Couselo, Eva
    Vidal, Maria
    Ortega, Vanessa
    Dienstmann, Rodrigo
    Aura, Claudia
    Prudkin, Ludmilla
    Vivancos, Ana
    Rodon Ahnert, Jordi
    Baselga, Jose
    Tabernero, Josep
    Cortes, Javier
    Saura, Cristina
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345